However, several drugs have been approved and clinically implemented for obesity caused by other genetic mutations in the MC4R pathway, as summarized in Table 4
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education and the Robert Wood Johnson Foundation
doi: Luz, Y., Calvi, I.P., Marques, I.R., Cruz, S.A., Messias, E., Emanuel, P., Azevedo, H., Cardoso, R., Moura, F.A
Tirzepatide: Dual GIP and GLP-1 activity Tirzepatide stimulates both GIP and GLP-1 receptors
What is the increased risk of NAION in patients using Ozempic for type 2 diabetes and obesity?
Understanding these dynamics is critical for optimizing the use of GLP-1based agents in disorders with central components, including neurodegeneration, psychiatric illness, and addiction